表紙
市場調査レポート

線維肉腫 : パイプライン分析

Fibrosarcoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321906
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
線維肉腫 : パイプライン分析 Fibrosarcoma - Pipeline Review, H2 2016
出版日: 2016年08月17日 ページ情報: 英文 64 Pages
概要

線維肉腫は、線維性結合組織から発生する悪性の腫瘍であり、症状は疼痛、腫れ、局所の熱感、血管拡張痛、骨の肥大、病的骨折、神経および血管の変化などが挙げられます。

当レポートでは、線維肉腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

線維肉腫の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • Advanced Proteome Therapeutics Corporation
  • Advenchen Laboratories, LLC
  • Elsalys Biotech SAS
  • Novartis AG
  • Plexxikon Inc.
  • Rigontec GmbH
  • 大日本住友製薬

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • DAL-3818
  • APC-103
  • DSR-6434
  • エベロリムス
  • ImOl-100
  • KRA-0008
  • LK-3
  • MAT-303
  • PLX-7486
  • SEN-461

最新のパイプライン情報

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8374IDB

Summary

Global Markets Direct's, 'Fibrosarcoma - Pipeline Review, H2 2016', provides an overview of the Fibrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma
  • The report reviews pipeline therapeutics for Fibrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fibrosarcoma therapeutics and enlists all their major and minor projects
  • The report assesses Fibrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fibrosarcoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Fibrosarcoma Overview 7
  • Therapeutics Development 8
  • Pipeline Products for Fibrosarcoma - Overview 8
  • Pipeline Products for Fibrosarcoma - Comparative Analysis 9
  • Fibrosarcoma - Therapeutics under Development by Companies 10
  • Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 11
  • Fibrosarcoma - Pipeline Products Glance 12
  • Late Stage Products 12
  • Clinical Stage Products 13
  • Early Stage Products 14
  • Fibrosarcoma - Products under Development by Companies 15
  • Fibrosarcoma - Products under Investigation by Universities/Institutes 16
  • Fibrosarcoma - Companies Involved in Therapeutics Development 17
  • Advanced Proteome Therapeutics Corporation 17
  • Advenchen Laboratories, LLC 18
  • Daiichi Sankyo Company, Limited 19
  • Elsalys Biotech SAS 20
  • Millennium Pharmaceuticals Inc 21
  • Novartis AG 22
  • Rigontec GmbH 23
  • Sumitomo Dainippon Pharma Co., Ltd. 24
  • Fibrosarcoma - Therapeutics Assessment 25
  • Assessment by Monotherapy Products 25
  • Assessment by Target 26
  • Assessment by Mechanism of Action 28
  • Assessment by Route of Administration 30
  • Assessment by Molecule Type 32
  • Drug Profiles 34
  • AL-3818 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • APC-103 - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • Cellular Immunotherapy for Oncology - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • DSR-6434 - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • everolimus - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • ImOl-100 - Drug Profile 53
  • Product Description 53
  • Mechanism Of Action 53
  • R&D Progress 53
  • LK-3 - Drug Profile 54
  • Product Description 54
  • Mechanism Of Action 54
  • R&D Progress 54
  • MAT-303 - Drug Profile 55
  • Product Description 55
  • Mechanism Of Action 55
  • R&D Progress 55
  • PLX-7486 - Drug Profile 56
  • Product Description 56
  • Mechanism Of Action 56
  • R&D Progress 56
  • sapanisertib - Drug Profile 57
  • Product Description 57
  • Mechanism Of Action 57
  • R&D Progress 57
  • SEN-461 - Drug Profile 60
  • Product Description 60
  • Mechanism Of Action 60
  • R&D Progress 60
  • SOM-0777 - Drug Profile 61
  • Product Description 61
  • Mechanism Of Action 61
  • R&D Progress 61
  • Fibrosarcoma - Dormant Projects 62
  • Appendix 63
  • Methodology 63
  • Coverage 63
  • Secondary Research 63
  • Primary Research 63
  • Expert Panel Validation 63
  • Contact Us 63
  • Disclaimer 64

List of Tables

  • Number of Products under Development for Fibrosarcoma, H2 2016 8
  • Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016 9
  • Number of Products under Development by Companies, H2 2016 10
  • Number of Products under Investigation by Universities/Institutes, H2 2016 11
  • Comparative Analysis by Late Stage Development, H2 2016 12
  • Comparative Analysis by Clinical Stage Development, H2 2016 13
  • Comparative Analysis by Early Stage Development, H2 2016 14
  • Products under Development by Companies, H2 2016 15
  • Products under Investigation by Universities/Institutes, H2 2016 16
  • Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2016 17
  • Fibrosarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 18
  • Fibrosarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 19
  • Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H2 2016 20
  • Fibrosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 21
  • Fibrosarcoma - Pipeline by Novartis AG, H2 2016 22
  • Fibrosarcoma - Pipeline by Rigontec GmbH, H2 2016 23
  • Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 24
  • Assessment by Monotherapy Products, H2 2016 25
  • Number of Products by Stage and Target, H2 2016 27
  • Number of Products by Stage and Mechanism of Action, H2 2016 29
  • Number of Products by Stage and Route of Administration, H2 2016 31
  • Number of Products by Stage and Molecule Type, H2 2016 33
  • Fibrosarcoma - Dormant Projects, H2 2016 62

List of Figures

  • Number of Products under Development for Fibrosarcoma, H2 2016 8
  • Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016 9
  • Number of Products under Development by Companies, H2 2016 10
  • Comparative Analysis by Clinical Stage Development, H2 2016 13
  • Comparative Analysis by Early Stage Products, H2 2016 14
  • Assessment by Monotherapy Products, H2 2016 25
  • Number of Products by Top 10 Targets, H2 2016 26
  • Number of Products by Stage and Top 10 Targets, H2 2016 26
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 28
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
  • Number of Products by Routes of Administration, H2 2016 30
  • Number of Products by Stage and Routes of Administration, H2 2016 30
  • Number of Products by Molecule Types, H2 2016 32
  • Number of Products by Stage and Molecule Types, H2 2016 32
Back to Top